solent pharma ltd
solent pharma ltd Company Information
Company Number
07450059
Next Accounts
Mar 2026
Shareholders
timothy wright
Group Structure
View All
Industry
Other professional, scientific and technical activities (not including environmental consultancy or quantity surveying) n.e.c.
Registered Address
murrills house 48 east street, portchester, hampshire, PO16 9XS
Website
www.solentpharma.comsolent pharma ltd Estimated Valuation
Pomanda estimates the enterprise value of SOLENT PHARMA LTD at £0 based on a Turnover of £0 and 0.6x industry multiple (adjusted for size and gross margin).
solent pharma ltd Estimated Valuation
Pomanda estimates the enterprise value of SOLENT PHARMA LTD at £0 based on an EBITDA of £-2k and a 4.34x industry multiple (adjusted for size and gross margin).
solent pharma ltd Estimated Valuation
Pomanda estimates the enterprise value of SOLENT PHARMA LTD at £28.9k based on Net Assets of £12.6k and 2.3x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Solent Pharma Ltd Overview
Solent Pharma Ltd is a live company located in hampshire, PO16 9XS with a Companies House number of 07450059. It operates in the other professional, scientific and technical activities n.e.c. sector, SIC Code 74909. Founded in November 2010, it's largest shareholder is timothy wright with a 100% stake. Solent Pharma Ltd is a established, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Solent Pharma Ltd Health Check
Pomanda's financial health check has awarded Solent Pharma Ltd a 1 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 1 areas for improvement. Company Health Check FAQs
1 Strong
0 Regular
1 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Solent Pharma Ltd
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Solent Pharma Ltd
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- Solent Pharma Ltd
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- Solent Pharma Ltd
- - Industry AVG
Employees
There is insufficient data available for this Key Performance Indicator!
- - Solent Pharma Ltd
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Solent Pharma Ltd
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Solent Pharma Ltd
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Solent Pharma Ltd
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Solent Pharma Ltd
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Solent Pharma Ltd
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 14 weeks, this is less cash available to meet short term requirements (26 weeks)
- - Solent Pharma Ltd
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 10.3%, this is a lower level of debt than the average (52.7%)
- - Solent Pharma Ltd
- - Industry AVG
SOLENT PHARMA LTD financials
Solent Pharma Ltd's latest turnover from June 2024 is estimated at 0 and the company has net assets of £12.6 thousand. According to their latest financial statements, we estimate that Solent Pharma Ltd has no employees and maintains cash reserves of £397 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||||||
| Other Income Or Grants | |||||||||||||
| Cost Of Sales | |||||||||||||
| Gross Profit | |||||||||||||
| Admin Expenses | |||||||||||||
| Operating Profit | |||||||||||||
| Interest Payable | |||||||||||||
| Interest Receivable | |||||||||||||
| Pre-Tax Profit | |||||||||||||
| Tax | |||||||||||||
| Profit After Tax | |||||||||||||
| Dividends Paid | |||||||||||||
| Retained Profit | |||||||||||||
| Employee Costs | |||||||||||||
| Number Of Employees | 2 | ||||||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 357 | 715 | 1,073 | ||||||||||
| Intangible Assets | |||||||||||||
| Investments & Other | |||||||||||||
| Debtors (Due After 1 year) | |||||||||||||
| Total Fixed Assets | 357 | 715 | 1,073 | ||||||||||
| Stock & work in progress | 1,968 | 1,968 | 1,968 | ||||||||||
| Trade Debtors | 31,591 | 41,022 | 39,825 | 563 | 3,105 | 4,064 | 2,089 | ||||||
| Group Debtors | |||||||||||||
| Misc Debtors | 13,654 | 13,072 | 17,811 | 13,034 | 19,044 | 8,182 | |||||||
| Cash | 397 | 2,348 | 7,072 | 13,263 | 10,770 | 14,287 | 10,069 | 46,146 | 70,896 | 94,252 | 213,056 | ||
| misc current assets | 6,530 | ||||||||||||
| total current assets | 14,051 | 15,420 | 24,883 | 26,297 | 29,814 | 22,469 | 38,121 | 41,022 | 51,862 | 48,677 | 75,969 | 98,316 | 215,145 |
| total assets | 14,051 | 15,777 | 25,598 | 27,370 | 29,814 | 22,469 | 38,121 | 41,022 | 51,862 | 48,677 | 75,969 | 98,316 | 215,145 |
| Bank overdraft | |||||||||||||
| Bank loan | |||||||||||||
| Trade Creditors | 755 | 7,833 | 712 | 712 | 2,825 | 70,869 | |||||||
| Group/Directors Accounts | |||||||||||||
| other short term finances | |||||||||||||
| hp & lease commitments | |||||||||||||
| other current liabilities | 1,450 | 850 | 850 | 825 | 800 | 1,470 | |||||||
| total current liabilities | 1,450 | 850 | 850 | 825 | 800 | 1,470 | 755 | 7,833 | 712 | 712 | 2,825 | 70,869 | |
| loans | |||||||||||||
| hp & lease commitments | |||||||||||||
| Accruals and Deferred Income | |||||||||||||
| other liabilities | |||||||||||||
| provisions | |||||||||||||
| total long term liabilities | |||||||||||||
| total liabilities | 1,450 | 850 | 850 | 825 | 800 | 1,470 | 755 | 7,833 | 712 | 712 | 2,825 | 70,869 | |
| net assets | 12,601 | 14,927 | 24,748 | 26,545 | 29,014 | 20,999 | 38,121 | 40,267 | 44,029 | 47,965 | 75,257 | 95,491 | 144,276 |
| total shareholders funds | 12,601 | 14,927 | 24,748 | 26,545 | 29,014 | 20,999 | 38,121 | 40,267 | 44,029 | 47,965 | 75,257 | 95,491 | 144,276 |
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||
| Operating Profit | |||||||||||||
| Depreciation | 357 | 358 | 358 | 358 | |||||||||
| Amortisation | |||||||||||||
| Tax | |||||||||||||
| Stock | -1,968 | 1,968 | |||||||||||
| Debtors | 582 | -4,739 | 4,777 | -6,010 | 10,862 | -23,409 | -9,431 | 1,197 | 39,262 | -2,542 | -959 | 1,975 | 2,089 |
| Creditors | -755 | -7,078 | 7,121 | -2,113 | -68,044 | 70,869 | |||||||
| Accruals and Deferred Income | 600 | 25 | 25 | -670 | 1,470 | ||||||||
| Deferred Taxes & Provisions | |||||||||||||
| Cash flow from operations | |||||||||||||
| Investing Activities | |||||||||||||
| capital expenditure | |||||||||||||
| Change in Investments | |||||||||||||
| cash flow from investments | |||||||||||||
| Financing Activities | |||||||||||||
| Bank loans | |||||||||||||
| Group/Directors Accounts | |||||||||||||
| Other Short Term Loans | |||||||||||||
| Long term loans | |||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||
| other long term liabilities | |||||||||||||
| share issue | |||||||||||||
| interest | |||||||||||||
| cash flow from financing | |||||||||||||
| cash and cash equivalents | |||||||||||||
| cash | -1,951 | -4,724 | -6,191 | 2,493 | -3,517 | 14,287 | -10,069 | -36,077 | -24,750 | -23,356 | -118,804 | 213,056 | |
| overdraft | |||||||||||||
| change in cash | -1,951 | -4,724 | -6,191 | 2,493 | -3,517 | 14,287 | -10,069 | -36,077 | -24,750 | -23,356 | -118,804 | 213,056 |
solent pharma ltd Credit Report and Business Information
Solent Pharma Ltd Competitor Analysis
Perform a competitor analysis for solent pharma ltd by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other established companies, companies in PO16 area or any other competitors across 12 key performance metrics.
solent pharma ltd Ownership
SOLENT PHARMA LTD group structure
Solent Pharma Ltd has no subsidiary companies.
Ultimate parent company
SOLENT PHARMA LTD
07450059
solent pharma ltd directors
Solent Pharma Ltd currently has 2 directors. The longest serving directors include Mr Timothy Wright (Apr 2011) and Mrs Ciara Wright (Feb 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Timothy Wright | 59 years | Apr 2011 | - | Director | |
| Mrs Ciara Wright | England | 54 years | Feb 2020 | - | Director |
P&L
June 2024turnover
0
0%
operating profit
-2.4k
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
June 2024net assets
12.6k
-0.16%
total assets
14.1k
-0.11%
cash
397
-0.83%
net assets
Total assets minus all liabilities
solent pharma ltd company details
company number
07450059
Type
Private limited with Share Capital
industry
74909 - Other professional, scientific and technical activities (not including environmental consultancy or quantity surveying) n.e.c.
incorporation date
November 2010
age
15
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
June 2024
previous names
N/A
accountant
BK PLUS LIMITED
auditor
-
address
murrills house 48 east street, portchester, hampshire, PO16 9XS
Bank
-
Legal Advisor
-
solent pharma ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to solent pharma ltd.
solent pharma ltd Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for SOLENT PHARMA LTD. This can take several minutes, an email will notify you when this has completed.
solent pharma ltd Companies House Filings - See Documents
| date | description | view/download |
|---|
